Head-to-head · Value Score
bmiMD vs Next Vial
Two GLP-1 deals, scored on the same six factors. bmiMD lands a Value Score of 89, Next Vial a 62. Here's who gives you the honest lower price — and where each one bites back.
bmiMD
#11 · Grade A · Great Deal
Est. first month
$99/mo
Save ~93% vs brand-nameNext Vial
#350 · Grade C · Watch List
Est. first month
From $250/mo (compounded)
Save ~81% vs brand-nameThe verdict
bmiMD takes it on Value Score, 89 to 62 — an est. $99/mo first month, with no teaser step-up baked in. Next Vial isn't out of it: People seeking compounded GLP-1 care with LegitScript certification and a named pharmacy partner.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | bmiMD | Next Vial |
|---|---|---|
| Value Score | 89 (A) | 62 (C) |
| Est. first month | $99/mo | From $250/mo (compounded) |
| Save vs brand-name | ~93% | ~81% |
| Semaglutide | $99/mo | From $250/mo (compounded) |
| Tirzepatide | $139/mo | Not disclosed |
| Both molecules | Yes | No |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | 49 states |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
bmiMD
Sub-$100 semaglutide and a low $139 tirzepatide, flat and nationwide — a straight-up low-price play.
Why it's a deal
- $99 flat semaglutide and a low $139 tirzepatide
- Available in all 50 states
- Both molecules priced up front
The fine print
- Not LegitScript-certified — do your own pharmacy diligence
- Thin public track record; no oral or brand-name option
Next Vial
Fully online GLP-1 telehealth marketplace connecting patients with licensed providers for compounded semaglutide and tirzepatide injections, including microdose options.
Why it's a deal
- LegitScript verified with named pharmacy partner (Manifest Pharmacy, Greer, SC)
- No membership fees — one all-in price covering consultation, medication, and shipping
- Compounded semaglutide, tirzepatide, and microdose options available
- Free rushed shipping; serves 49 states nationwide
- Board-certified physician oversight with ongoing provider support
The fine print
- Tirzepatide pricing not listed publicly (starting price covers GLP-1 generally)
- Compounded medications are not FDA-approved
- Labs and nutritional coaching not disclosed
- Microdose pricing not published on product page
- Alaska not listed among served states
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores bmiMD is ranked on the bmiMD alternatives board, and the same list for the other side is on alternatives to Next Vial.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.